玻璃体腔注射康柏西普治疗葡萄膜炎继发黄斑水肿疗效观察

摘要/Abstract

摘要： 目的：评估玻璃体腔注射康柏西普治疗葡萄膜炎继发黄斑水肿的临床疗效。方法：选取2013年7月至2015年9月我院门诊收治的24例33眼葡萄膜炎继发黄斑水肿患者作为研究对象，依据治疗方法分为两组：玻璃体腔注射康柏西普治疗组（康柏西普组，n=12，17眼）和玻璃体腔注射曲安奈德治疗组（曲安奈德组，n=12，16眼）。采用最佳矫正视力(BCVA)、荧光素眼底血管造影术(FFA)、光学相干断层扫描技术/光学相干层析成像（OCT）及中央视网膜厚度（CRT）评估治疗6个月后药物临床疗效。结果：治疗前两组患者BCVA、OCT之间的差异均无统计学意义（P＞0.05），治疗后6个月与曲安奈德组相比，康柏西普组患者的BCVA显著较高，差异有统计学意义（P＜0.05），OCT显著较低，差异有统计学意义（P＜0.05）；和治疗前相比，治疗后6个月两组患者BCVA显著较高，差异有统计学意义（P＜0.05），OCT显著较低，差异有统计学意义（P＜0.05）。FFA检查：治疗的24例33眼中，均未发现新的出血部位，也没有新的血管形成；其中13例患者19只患眼黄斑部渗漏病变，相较治疗前范围减小，另外11例14眼黄斑部已观察不到病变。康柏西普组患者治疗的总有效率94.1%（16/17）显著高于曲安奈德组75.0%（12/16），差异有统计学意义（P＜0.05）。曲安奈德组并发症发生率为35.3%，康柏西普组并发症发生率为25.0%，两组患者并发症发生率之间的差异无统计学意义（P＞0.05）。结论：玻璃体腔注射康柏西普能有效治疗葡萄膜炎继发黄斑水肿，治疗后患者视力稳定。

Abstract: Objective：To determine the therapeutic effect of intravitreal injection of conbercept ophthalmic injection (conbercept) for the treatment of uveitic cystoid macular edema.Methods：24 patients of 33 eyes with uveitic cystoid macular edema treated by intravitreal injection of conbercept during July 2013 to September 2015 were divided into two groups： intravitreal injection of conbercept ophthalmic injection treatment group (conbercept，n=12，17 eyes) and intravitreal injection of triamcinolone acetonide injection treatment group (triamcinolone acetonide group，n=12，16 eyes)according to the treatment methods.The best corrected visual acuity（BCVA），fluorescein fundusangiography(FFA)，optical coherence tomography（OCT）and central retinal thickness（CRT）were observed on the therapeutic effect of drug after 6 months.Results：Before treatment，the differences of BCVA and OCT between the two groups of patients were not statistical significant(P＞0.05). Compared with the triamcinolone acetonide group，the BCVA of the conbercept group after 6 months treatment was significantly higher， there was statistical significance(P＜0.05)，the OCT was significantly lower， there was statistical significance(P＜0.05).Compared with before treatment，the BCVA after 6 months treatment of the two groups of patients was significantly higher， there was statistical significance(P＜0.05)，the OCT was significantly lower， there was statistical significance (P＜0.05).FFA examination： no new bleeding site were found in 33 eyes of 24 cases， and no new blood vessels were formed.Of them，13 cases of patients had 19 eyes with macular leakage. Compared with before treatment，the range of them decreased，and 11 cases of 14 eyes were not observed in macular.The total effective rate 94.1% (16/17) of the compaitcept group was significantly higher than the triamcinolone acetonide group 75.0% (12/16)， there was statistical significance (P＜0.05).The incidence of complication rate of triamcinolone acetonide group was 35.3%， the incidence of complication of the conbercept group was 25.0%， the difference between two groups was not statistical significant(P＞0.05).Conclusion：Intravitreal injection of conbercept can be effective in the treatment of uveitic cystoid macular edema and patients with stable vision after injection.

张小玲,宋徽,肖云,高晓唯,张燕. 玻璃体腔注射康柏西普治疗葡萄膜炎继发黄斑水肿疗效观察[J]. .

ZHANG Xiaoling,SONG Hui,XIAO Yun,GAO Xiaowei and ZHANG Yan. Observation of Therapeutic Effect of Intravitreal Injection of Conbercept for Uveitic Cystoid Macular Edema[J]. .

参考文献

[1] Taraborelli M,Cavazzana I,Fredi M,et al.Treatment and functional outcome of patients with cystoid macular edema: a single-center experience[J].Clin Rheumatol,2015,34(4):791-794.
[2] Switu?a M.Complete and permanent regression of persistent uveitic cystoid macular edema after single intravitreal iniection of aflibercept in patient previously treated with multiple intravitreal injections of ranibizumab and bevacizumab[J].Klin Oczna,2015,117(1):31-34.
[3] Slean GR,Khurana RN.Local therapeutic options for uveitic cystoid macular edema[J].Int Ophthalmol Clin,2015,55(3):39-61.
[4] Tranos PG,Tsaousis KT,Vakalis AN,et al.Long-term follow-up of inflammatory cystoid macular edema[J].Retina,2012,32(8):1624-1628.
[5] Garweg JG,Baglivo E,Freiberg FJ,et al.Response of Postoperative and Chronic Uveitic Cystoid Macular Edema to a Dexamethasone-Based Intravitreal Implant (Ozurdex)[J].J Ocul Pharmacol Ther,2016,32(7):442-450.
[6] Hussain RM,Ciulla TA.Treatment strategies for refractory diabetic macular edema: switching anti-VEGF treatments, adopting corticosteroid-based treatments, and combination therapy[J].Expert Opin Biol Ther,2016,16(3):365-374.
[7] Jeon S,Lee W K,Jung Y.Changes in the intraocular cytokine levels after intravitreal bevacizumab in uveitic macular edema[J].Ocul Immuno & Inflamm,2012,20(5):360-364.
[8] Loukianou E,Brouzas D,Chatzistefanou K,et al.Clinical, anatomical, and electrophysiological assessments of the central retina following intravitrealbevacizumab for macular edema secondary to retinal vein occlusion[J].Int Ophthalmol,2016,36(1):21-36.
[9] Nowacka B,Kirkiewicz M,Mozolewska-Piotrowska K,et al.The macular function and structure in patients with diabetic macular edema before and afterranibizumab treatment[J].Doc Ophthalmol,2016,132(2):111-122.
[10] Nuzzi R,Tridico F.Local and systemic complications after intravitreal administration of anti-vascular endothelial growth factor agents in the treatment of different ocular diseases: a five-year retrospective study.[J].Seminars in ophthalmology,2013,30(2):129-135.
[11] Wang F,Bai Y,Yu W,et al.Anti-angiogenic effect of KH902 on retinal neovascularization[J].G raefe’s Arch Clin Exp Ophthalmal,2013,251(9):2131-2139.
[12] 余岚,陈长征,易佐慧子.玻璃体腔注射康柏西普治疗渗出型老年性黄斑变性的疗效观察[J]. 中华眼底病杂志, 2015, 31(3):256-259.
[13] 张菁,蔡小军,陈晓敏.玻璃体腔注射康柏西普联合视网膜激光光凝治疗视网膜分支静脉阻塞继发黄斑水肿疗效观察[J].中华眼底病杂志,2015,31(1):22-26.
[14] Loukianou E,Brouzas D,Chatzistefanou K,et al.Clinical, anatomical, and electrophysiological assessments of the central retina following intravitreal bevacizumab for macular edema secondary to retinal vein occlusion[J].Int Ophthalmol,2016,36(1):21-36.
[15] Bakri SJ,Larson TA.The variable efficacy of intravitreal bevacizumab and triamcinolone acetonide for cystoid macular edema due to radiation retinopathy[J].Semin Ophthalmol,2015,30(4):276-280.
[16] Reddy A K,Cabrera M,Yeh S,et al.Optical coherence tomography-guided ranibizumab injection for cystoid macular edema in well-controlled uveitis: twelve-month outcomes[J].Retina, 2014,34(12):2431-2438.
[17] Li X, Xu G, Wang Y,et al.Safety and efficacy of conbercept in neovascular age-related macular degeneration: results from a 12-month randomized phase 2 study: AURORA study[J].Ophthalmology,2014,121(9):1740-1747.
[18] Nguyen TT, Guymer R.Conbercept (KH-902) for the treatment of neovascular age-related macular degeneration[J].Expert Rev Clin Pharmacol,2015,8(5):541-548.
[19] 罗光伟,江福钿,文峰.多焦视网膜电图在Vogt-小柳原田病急性期及恢复期随访中的应用[J]. 中华实验眼科杂志,2011,29(8):718-723.
[20] Wang L,Liu J,Lu T.Clinical analysis of early and mid-late elevated intraocular pressure after silicone oil injection[J].Eye Sci,2014,29(2):85-89.
[21] Deissler HL,Lang GK,Lang GE.Internalization of bevacizumab by retinal endothelial cells and its intracellular fate: Evidence for an involvement of the neonatal Fc receptor[J].Exp Eye Res,2016,143:49-59.

快速检索引用检索图表检索高级检索